Proteomic approaches in myeloid leukemia.
After human genome is decoded, the characterization of the proteins is the next challenging task. The study of the complete protein complement of the genome, the 'proteome' referred to as proteomics, is an important tool for the identification of new therapeutic targets. Research efforts are underway to develop the technology necessary to compare the specific protein profiles of diseased versus healthy states. These technologies provide a wealth of information by rapidly generating large quantities of data. These data can be useful for predictive mathematical descriptions of biological systems for rapid identification of novel therapeutic targets and identification of biomarkers in metabolic disorders. In recent years, using proteomics, we and others have identified various interacting as well as target proteins, PTMs and protein markers in myeloid leukemia. This review summarizes the usage of proteomics in recent years as an important technique in defining the proteome of myeloid leukemia, which has helped in elaborate understanding of the disease and has provided new avenues for developing better therapeutics.
Drug Target Discovery and Development Division, Central Drug Research Institute, Lucknow, India.
Jitendra Kumar
JK
Kanaujiya
Savita
S
Lochab
Pooja
P
Pal
Maximilian
M
Christopeit
Sheo Mohan
SM
Singh
Sabyasachi
S
Sanyal
Gerhard
G
Behre
Arun Kumar
AK
Trivedi
D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000032:analysis* / Q000235:genetics; D019937:Diagnostic Techniques and Procedures; D015195:Drug Design; D005819:Genetic Markers; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008958:Models, Molecular; D009154:Mutation / Q000235:genetics; D011506:Proteins; D020543:Proteome / Q000032:analysis / Q000378:metabolism; D040901:Proteomics / Q000295:instrumentation* / Q000379:methods*
D022763:CCAAT-Enhancer-Binding Protein-alpha; D005819:Genetic Markers; D011506:Proteins; D020543:Proteome